AIM ImmunoTech Inc. announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen(R) as a potential therapeutic for people with post-COVID conditions ("AMP-518"). The study has met the planned enrollment of 80 AMP-518 subjects ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with a follow-up phase of two weeks. The ompany expects to complete dosing of the last study patient in Fourth Quarter 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.388 USD | -5.48% | -1.15% | -12.37% |
16/05 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
29/04 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.37% | 2.09Cr | |
+10.44% | 12TCr | |
+12.77% | 11TCr | |
-4.42% | 2.47TCr | |
-2.33% | 2.2TCr | |
-6.03% | 1.93TCr | |
-10.96% | 1.76TCr | |
-39.36% | 1.73TCr | |
+6.62% | 1.4TCr | |
+32.48% | 1.21TCr |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions